Labcorp (LH)
(Delayed Data from NYSE)
$198.40 USD
+0.05 (0.03%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $198.28 -0.12 (-0.06%) 4:28 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
Price, Consensus and EPS Surprise
LH 198.40 +0.05(0.03%)
Will LH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LH
Integer Holdings (ITGR) Q1 Earnings Top Estimates, Margins Up
3 Medical Products Stocks Set to Beat This Earnings Season
LH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Other News for LH
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Laboratory (LH), Fusion Pharmaceuticals (FUSN) and Integer Holdings (ITGR)
Labcorp price target lowered by $11 at Baird, here's why
Labcorp price target lowered by $21 at Barclays, here's why
Weitz Conservative Allocation Fund Q1 2024 Commentary
Weitz Multi Cap Equity Fund Q1 2024 Commentary